What were the key takeaways from Milestone Scientific's earnings call?

What is Milestone Scientific's gross profit margin?

What is the revenue and EPS growth rate for Milestone Scientific year over year?

Did Milestone Scientific beat or miss consensus estimates last quarter?

What factors drove the changes in Milestone Scientific's revenue and profit?

What were the key takeaways from Milestone Scientific’s earnings call?

What does Milestone Scientific do and what are its main business segments?

What is Milestone Scientific's latest dividend and current dividend yield?

- **Revenue Surge**: 25% YoY growth to $2.3M, fueled by 100%+ gains in medical and international sales.
- **Strategic Shift**: Direct-to-consumer dental model boosts margins, while medical focuses on 3-5 key clinics for reimbursement validation.
- **Key Hires**: New sales leader and Board member to accelerate medical adoption and federal partnerships.
- **Cash Position**: $1.3M cash, solid liquidity for growth initiatives.
- **Risks**: Lumpy international sales and slow medical adoption, but strong product performance in clinical use.

**【CEO Summary Section】**
- **Revenue Growth**: Q2 revenue increased 25% YoY to $2.3 million, driven by a 100% surge in international dental sales and a 267% rise in medical revenue.
- **Dental Segment Strategy**: Shifted to direct-to-consumer e-commerce model, reducing distribution costs and improving margins. U.S. dental sales were flat but expected to grow with targeted marketing.
- **Medical Segment Progress**: Secured Medicare Part B reimbursement in New Jersey, Texas, and Florida. Early adoption by pain management clinics, with 5-10 active users.
- **Leadership Expansion**: Hired Jason Papes as Global Head of Sales and Marketing, and added Shanth Thiyagalingam to the Board for reimbursement expertise.
- **Focus Areas**: Accelerate CompuFlo Epidural adoption in pain management clinics, expand international dental sales, and pursue VA/DoD partnerships.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: Dental ($2.0M, +25%), Medical ($32K, +133%), International ($1.0M, +103%).
- **Gross Profit**: $1.6M (69% margin), up 15% YoY.
- **Expenses**: SG&A $3.0M (+3.4%), R&D $52K (-85%).
- **Liquidity**: $1.3M cash, $3.9M working capital, no debt.

**【Q&A Highlights】**
- **Medical Adoption Strategy**: Focus on 3-5 key clinics to collect reimbursement data, then scale. Targeted federal partnerships (VA/DoD) for faster adoption.
- **International Growth**: 48% of revenue from international, driven by new distributors and direct shipments from China to avoid tariffs.
- **VA Progress**: Engaged with Shamrock to pilot CompuFlo in eastern VA facilities, with favorable pricing terms.
- **Brazil Update**: On hold due to U.S.-Brazil trade tensions, but long-term potential remains.
- **Product Performance**: No reported wet taps or short taps in clinical use, validating STA and CompuFlo reliability.

MLSS

MLSS fundamentals

You can ask Aime